Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push
Sees Magic In ‘Neural Dust’ Implant Tech
Executive Summary
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
You may also be interested in...
Astellas Eyes Doubling Market Cap On Core, Focus Assets
Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.